Avid Bioservices Inc (CDMO)

[porkchop11]

Second-line NSCLC: This randomized, double-blinded, placebo-controlled Phase II trial is evaluating bavituximab with docetaxel versus docetaxel with placebo in 121 second-line NSCLC patients. Top-line data from the trial announced in May 2012 showed a doubling of overall response rates (ORR), the primary endpoint, and an improvement in progression-free survival (PFS), a secondary endpoint, in patients treated in the bavituximab-containing arms when compared to the control arm. Another secondary endpoint, median overall survival (OS), in the control arm has already been determined at less than 6 months, while as of May 2012 the median OS had not been reached in either bavituximab-containing arm.


my final attempt to post this (server hangup); just p2 2nd line overview (as opposed to 1st line).

mos is a secondary endpoint in the 2nd line, which has not been met for the bavi arms. And note the doubling of orr...placebo my ass.

all imo.

porkchop11